Role of a Urinary Biomarker in the Common Mechanism of Physical Performance and Cognitive Function

Abstract

IntroductionHealthy aging is described as a process of developing and maintaining intrinsic abilities, including physical and cognitive functions. Although oxidative stress is a common mechanism shared by loss of muscle strength and dementia, its relationship with decreased physical performance and cognitive impairment remains unclear. We aimed to investigate the role of urinary 8-oxo-7, 8-dihydroguanosine (8-oxoGsn), a biomarker of oxidative damage to RNA, in physical and cognitive decline.MethodsThe study followed a cross-sectional design and recruited 40–94-year-old inhabitants of Beijing, China (471 men and 881 women). The physical performance of the participants was assessed using handgrip strength, walking speed, and the repeated chair stand test. The cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) 5-min protocol. Urinary 8-oxoGsn levels were measured for all participants.ResultsParticipants with high urinary 8-oxoGsn levels were more likely to have low grip strength, slow walking speed, poor performance in the repeated chair stand test, and low scores on the MoCA 5-min protocol (odds ratio [OR] 3.43, 95% confidence interval [CI]: 1.52–7.76; OR 1.71, 95% CI: 1.16–2.53; OR 2.06, 95% CI: 0.92–4.63; OR 1.75, 95% CI: 1.18–2.58), after adjusting for age, sex, smoking habits, alcohol consumption, hypertension, diabetes, cerebro-cardiovascular disease, and chronic kidney disease.ConclusionElevated levels of oxidative stress are independently associated with cognitive and physical impairment. Thus, these results can help in the early identification and development of strategies for the prevention and treatment of intrinsic capacity decline.

Understanding exogenous factors and biological mechanisms for cognitive frailty: a multidisciplinary scoping review

“…The European muti-centre MARK-AGE study analysed biomarkers in more than 2000 older adults and found lower levels of antioxidants, including β-cryptoxanthin and zeaxanthin, in those who were physically, cognitively, or psychologically frail (Rietman, Spijkerman, et al, 2019). Jiang et al, (2022) found that a urinary biomarker, 8-oxoGsn, was associated with poor physical performance and worse cognitive function, relationships persisting once several confounders including age were controlled for, suggesting levels may be a useful indicator for early screening for MCI in frail patients and could be used to determine efficacy of anti-oxidative stress interventions.…”

“…(Rietman, Spijkerman, et al, 2019). Jiang et al, (2022) found that a urinary biomarker, 8-oxoGsn, was associated with poor physical performance and worse cognitive function, relationships persisting once several confounders including age were controlled for, suggesting levels may be a useful indicator for early screening for MCI in frail patients and could be used to determine efficacy of anti-oxidative stress interventions.…”

The Role of Oxidative Stress and Inflammatory Parameters in Heart Failure

“…8-Hydroxyguanosine 8-Hydroxyguanosine (8-oxo(d)G) is an extensively studied product of nucleic acid oxidation formed by guanine oxidation, disrupting DNA pairing and causing gene mutations [79,83]. 8-oxoGsn, a metabolite reflecting oxidative damage to RNA, plays a significant role in heart disease through its association with oxidative stress [83][84][85][86]. Elevated levels of urinary 8-oxoGsn, indicative of RNA oxidative damage, have been linked to poor physical performance and cognitive impairment, suggesting a relationship between oxidative stress and a decline in these functions, which are also common in heart disease [83,84].…”

“…Therefore, urinary 8-oxoGsn may serve as a valuable biomarker for assessing oxidative damage and evaluating the progression of heart disease. However, further research is needed to confirm these findings and establish causality, as well as to identify associated risk factors and determine the utility of urinary 8-oxoGsn in clinical practice for managing heart disease [85,87]. 6.2.6.…”